Deciphera expands cancer trial after seeing early data

Deciphera Pharmaceuticals has posted data from a phase 1 trial of its small molecule switch control inhibitor of CSF1R, DCC-3014. The early-phase data have emboldened Deciphera to expand the trial to include patients with tenosynovial giant cell tumors (TGCTs).